Antidepressant Therapy

Results showed patients with depression who received antidepressants within 6 months prior to total hip or knee arthroplasty had greater improvements in outcomes at 2 years compared with patients with depression who were untreated.

The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major depressive disorder in patients aged 15 to 21 years, according to the manufacturer.

Continuing adjunctive antidepressant therapy for 52 weeks after depressive episode remission in patients with bipolar 1 disorder did not significantly delay further mood episodes vs. stopping treatment after 8 weeks, according to a study.

Patients in primary care practices who “felt well enough” to stop certain antidepressants — and did so — were at higher risk for relapse of depression by 52 weeks compared with those who continued therapy, researchers wrote.

Esketamine nasal spray appeared to rapidly reduce depressive symptoms among severely ill patients with major depressive disorder who had active suicidal ideation with intent, according to a study published in Journal of Clinical Psychiatry.

Long-term esketamine nasal spray plus a new oral antidepressant appeared safe and tolerable among patients with treatment resistant depression, according to results of a phase 3, open-label, multicenter, long-term study published in Journal of Clinical Psychiatry.

An analysis of medical records from a large German endocrine clinic suggests more transgender men are seeking gender-affirming treatment, with nearly all individuals reporting an improvement in their overall situation after initiating hormone therapy, according to findings published in Clinical Endocrinology.

Researchers of a published study found both short- and long-term use of selective serotonin reuptake inhibitors was associated with increased risk for hip fracture among patients on hemodialysis.